Shockwave IVL

Class 5 (Live Case) - Eccentric and Ostial Lesions - Focus on Best Practices

11 June

10:30 AM America/New_York

1H 40M

Watch Recording
Join us to understand what makes ostial lesions difficult to treat and how to address these challenges.

We will be featuring a live case of calcium modification from St Francis’ Hospital in New York and investigating the treatment of eccentric calcific coronary artery disease.
Videos open video

Shockwave IVL

LIVE - Class 5 (Live Case) - Eccentric and Ostial Lesions - Focus on Best...

open video

Shockwave IVL

Class 5 (Live Case) - Eccentric and Ostial Lesions - Focus on Best Practices


Allen Jeremias

Allen Jeremias, MD, MSc, is the Director of Interventional Cardiology Research and Associate Director of the Cardiac Catheterization Laboratory at St. Francis Hospital in Roslyn, New York. He is also a member of the Cardiovascular Research Foundation in New York City where he currently serves as the Director of the Physiology Core Laboratory. He completed his medical training at The Cleveland Clinic Foundation, Stanford University School of Medicine, and Harvard Medical School. He has been a high volume interventional cardiologist since 2006 and recognized as a Top Doctor in the New York Metro Area by Castle Connolly. Dr. Jeremias has significantly contributed to advancing the field of interventional cardiology and he is considered one of the foremost authorities in coronary physiology and intravascular imaging. He is a co-director of the annual St. Francis Intravascular Imaging and Coronary Physiology Workshop, teaching physicians around the world on “Precision Angioplasty”. Dr. Jeremias is presently engaged in a major global study that could change the path of treating clogged arteries. Known as the ILUMIEN IV trial, this major clinical study is evaluating Optical Coherence Tomography (OCT) to guide coronary stent placement. He is also the principal investigator of DEFINE PCI, an international study on assessing the improvement in blood flow after stent placement for severe coronary blockages.

Carlo Di Mario

Carlo Di Mario is Professor of Cardiology at the University of Florence and Director of the Structural 
Interventional Cardiology Division of the University Hospital Careggi, Florence, Italy. Previous posts included 15 years as Professor of Clinical Cardiology at Imperial College of Sciences, Medicine & Technology, London and Consultant Cardiologist at the Royal Brompton Hospital. Despite his teaching, research and administrative commitments, he maintains an active clinical involvement performing more than 100 PCI per year with special interest in the treatment of calcified lesions, chronic total occlusions, bifurcations, and diffuse disease. He is a regular TAVI operator and certified implanter for the Medtronic Evolut R and Edwards Sapien 3 transcatheter aortic valves. He participated in more than 160 MitraClip implantations in London and Florence and has recently started direct annuloplasty with the CardioBand. Professor Di Mario pioneered the use of intracoronary Doppler, pressure measurement, intravascular ultrasound, optical coherence tomography, and near infrared spectroscopy. He was PI of the OPTICUS trial, failing to demonstrate superiority of IVUS guided stenting, and of the Lipid Rich Plaque study, due to report at TCT 2018. He was Principal Investigator of the DESTINI trial, using Doppler CRF to identify lesions in need of stenting, and of the CARESS in AMI trial, a large multicentre trial showing that patients who receive fibrinolytic therapy for ST-elevation myocardial infarction benefit from early angioplasty. This trial and a subsequent meta-analysis have led to a change in the European Society of Cardiology and AHA/ACC Guidelines for treatment of STEMI patients. He cooperated with Dr Davies to the validation of iFR to assess lesion severity and discriminate the contribution of individual lesions, and with Dr Lyon in the intracoronary delivery of SERCA-2 genes via adenoviral vectors in the CUPID2 trial.

James Spratt

Prof James C Spratt has global experience in training physicians in complex and CTO PCI. He is the Director of Optimal CTO and the author of the Retrograde iBook and co-author of the antegrade iBook.

Julian Strange

An interventional cardiologist at University Hospital of Bristol, Bristol, UK. Features in 17 videos on Wondr Medical. Julian Strange generally speaks on Chronic Total Occlusion (CTO), Primary Percutaneous Coronary Intervention (PPCI), Bifurcation, Left Main Stem (LMS), and Coronary Interventions.

Nicolas Van Mieghem

Professor Nicolas M. Van Mieghem is the clinical director of Interventional Cardiology and full professor of interventional cardiology at Thoraxcenter, Erasmus University – Rotterdam, Netherlands. His reserach interest is in complex (calcified) coronary lesions, mechanical circulatory support and structural heart interventions. He is involved in the percutaneous coronary interventions and structural heart program. He has published and co-authored approximately 130 scientific papers in peer-reviewed journals. He is also taking part in multiple ongoing international trials evaluating various coronary and transcatheter valve technologies.

Richard Shlofmitz

Dr Richard A. Shlofmitz, MD, FACC is the Chairman of Cardiology at St. Francis Hospital, The Heart Center®, in Roslyn, New York. A pioneer in interventional cardiology, Dr. Shlofmitz has worked to advance the field, with a focus on optimizing outcomes with the development of Precision PCI. He is a founding co-director of the annual Intravascular Imaging and Coronary Physiology Workshop. Performing over 1,000 coronary interventions annually, he has one of the largest volumes of experience in PCI. He has the most clinical experience with orbital atherectomy and OCT world-wide. His clinical research interests focus on optimizing coronary interventions and he serves on multiple scientific advisory boards and clinical trial steering committees to further this mission. Dr Shlofmitz has been one of the largest enrollers for multiple clinical trials, including TWILIGHT, ILUMIEN III, and Onyx, with more than 75 publications in peer-reviewed journals and was first to perform coronary intravascular lithotripsy (IVL) in North America as part of the DISRUPT CAD III trial.


Class 5 (Live Case) - Eccentric and Ostial Lesions - Focus on Best Practices

Join us to understand what makes ostial lesions difficult to treat and how to address these challenges.

We will be featuring a live case of...
Read More

10:30 AM - 10:50 AM America/New_York

Calcific ostial coronary disease: a different challenge

With Julian Strange

Components/UI/Add-Calendar/Calendar-L Add to calendar

10:50 AM - 11:50 AM America/New_York

Live case from St Francis Hospital, New Jersey

With Allen Jeremias and Richard Shlofmitz

Components/UI/Add-Calendar/Calendar-L Add to calendar

11:50 AM - 12:10 PM America/New_York

Treating eccentric coronary arterial calcium

With Carlo Di Mario

Components/UI/Add-Calendar/Calendar-L Add to calendar